dc.contributor.author | Schmid, P | en_US |
dc.contributor.author | Pinder, SE | en_US |
dc.contributor.author | Wheatley, D | en_US |
dc.contributor.author | Macaskill, J | en_US |
dc.contributor.author | Zammit, C | en_US |
dc.contributor.author | Hu, J | en_US |
dc.contributor.author | Price, R | en_US |
dc.contributor.author | Bundred, N | en_US |
dc.contributor.author | Hadad, S | en_US |
dc.contributor.author | Shia, A | en_US |
dc.contributor.author | Sarker, S-J | en_US |
dc.contributor.author | Lim, L | en_US |
dc.contributor.author | Gazinska, P | en_US |
dc.contributor.author | Woodman, N | en_US |
dc.contributor.author | Korbie, D | en_US |
dc.contributor.author | Trau, M | en_US |
dc.contributor.author | Mainwaring, P | en_US |
dc.contributor.author | Gendreau, S | en_US |
dc.contributor.author | Lackner, MR | en_US |
dc.contributor.author | Derynck, M | en_US |
dc.contributor.author | Wilson, TR | en_US |
dc.contributor.author | Butler, H | en_US |
dc.contributor.author | Earl, G | en_US |
dc.contributor.author | Parker, P | en_US |
dc.contributor.author | Purushotham, A | en_US |
dc.contributor.author | Thompson, A | en_US |
dc.date.accessioned | 2016-08-15T11:58:17Z | |
dc.date.available | 2015-12-14 | en_US |
dc.date.issued | 2016-06-10 | en_US |
dc.date.submitted | 2016-01-05T19:14:47.802Z | |
dc.identifier.issn | 0732-183X | en_US |
dc.identifier.other | 10.1200/JCO.2015.63.9179 | |
dc.identifier.uri | http://qmro.qmul.ac.uk/xmlui/handle/123456789/14490 | |
dc.description.sponsorship | Supported by the National Institute for Health Research and Cancer Research UK funding (to Barts/Brighton Experimental Cancer Medicine Centre for the OPPORTUNE trial). Recruitment in the United Kingdom was supported by the National Institute for Health Research Cancer Research Network and the UK Experimental Cancer Medicine Centre network. Additional funding and study medication were provided by Genentech, South San Francisco, CA. Next-generation sequencing analysis was supported by Grant No. CG-12-07 from the National Breast Cancer Foundation of Australia (M.T.). | en_US |
dc.format.extent | 1987 - + | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | JOURNAL OF CLINICAL ONCOLOGY | en_US |
dc.title | Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer | en_US |
dc.type | Article | |
dc.rights.holder | © 2016 by American Society of Clinical Oncology | |
dc.identifier.doi | 10.1200/JCO.2015.63.9179 | en_US |
pubs.author-url | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000377378400006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
pubs.issue | 17 | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 34 | en_US |